leisure time -WSS

leisure time

author：explore 2025-09-03 05:33:12 - browse：623

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： RSV vaccines may be linked to small increased risk of developing GBS

focus

WSS

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

FDA does about

Obamacare plans could cover weight loss drugs

Why getting cancer drugs just got harder for rural patients

An inside look at PIPEs, biotech's buzzy new financing tool

Opioid cravings were reduced by anti

knowledge

leisure time

entertainment

Peter Hotez and the public health issue of online harassment

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Alkermes shareholders re

House looks to weaken Medicare negotiation

The cancer drug shortage isn’t new — and neither are the solutions

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Jerome Adams on the need for new antivirals for Covid

Secretariat’s lessons for human medicine

Wikipedia

Abridge raises $150m as clinical notes automation market heats up

Change Healthcare cyberattack outage could last weeks

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Researchers tackle phage therapy hurdles for wider adoption

Hospitals are piloting generative AI tools as regulators play catch

Biotech companies concerned about China biosecurity crackdown

focus

knowledge

knowledge

entertainment